CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Lotus Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Lotus Pharmaceuticals Inc
16 Cheng Zhuang Road, Feng Tai District
Phone: +86 1063899868p:+86 1063899868 BEIJING, BEJ  100071  China Ticker: LTUS LTUS
This company ceased filing statements with the SEC on 5/11/2012.
Business Summary
Lotus Pharmaceuticals, Inc. (Lotus) develops, manufactures, and sells pharmaceuticals in the China. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. Its drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. It operates, controls and owns the pharmaceutical businesses in China of Beijing Liang Fang Pharmaceutical Co., Ltd. (Liang Fang) and Beijing En Zhe Jia Shi Pharmaceutical Co., Ltd. (En Zhe Jia), collectively Lotus East. Lotus East is engaged in the production, trade and retailing of pharmaceuticals, focusing on the development of medicines and investing in strategic growth to address various medical needs. Lotus East owns and operates 10 drug stores throughout Beijing, China that sell Western and traditional Chinese medications, and generate revenues from the leasing of retail space to third party vendors in its retail stores.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201112/31/2010YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
5900 Miscellaneous retail
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer ZhongyiLiu 50 9/1/2006 9/1/2006
Chief Financial Officer YanZeng 55 9/22/2010 5/1/2009
Vice President - Corporate Development XingShen 40 9/22/2010 9/22/2010
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Aztic II HoldCo
Aztic Pharma Partners
En Zhe Jia Shi Pharmaceutical, Ltd.
9 additional Business Names available in full report.

General Information
Number of Employees: 233 (As of 12/31/2010)
Outstanding Shares: 2,694,515,543 (As of 9/30/2022)
Shareholders: 58
Stock Exchange: OTC
Federal Tax Id: 200507918
Fax Number: +86 1063899867


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, August 30, 2023